Translatum Medicus Developing Option To Treat Dry AMD
Clinicians have few treatment options for dry AMD, but Translatum Medicus Inc., is working on an agent, TMi-018, for such an indication. President and CSO Shelley Boyd, MD, FRCSC, explained the company has reverse engineered an animal model to mimic the disease so investigators can test treatments. TMi-018 is a first-in-class transcriptional modulator that is already demonstrated safety in phase II and III trials for autoimmune disease.
Presenter:
Shelley Boyd, MD, FRCSC
Shelley Boyd, MD, FRCSC, is an Ophthalmologist specializing in diseases of the retina and founding President & CSO of Translatum Medicus Inc(TMi). She trained at the University of Toronto, with fellowships at Moorfields Eye Hospital, UK and the Scripps Research Institute, California.